{"filings":[{"id":97603,"accession_number":"0001193125-26-212109","cik":2078856,"company_name":"Hyperliquid Strategies Inc","ticker":"PURR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Hyperliquid Strategies Q3 net profit of $152.5M on HYPE gains; treasury grows to 20M tokens","event_type":"earnings","confidence":"high","bullets":["Q3 net profit of $152.5M, driven by $198.4M unrealized gains on HYPE tokens, partially offset by $42.7M deferred tax expense.","Nine-month net loss of $165.4M, including $64M unrealized losses on HYPE and $35.6M IPR&D write-off from legacy bio-tech.","Total assets of $809.4M as of March 31, 2026; stockholders' equity of $743.5M with no debt.","Treasury holds 20.0M HYPE tokens (as of April 29, 2026) and $103M in cash; $216M deployed to accumulate HYPE since inception.","Repurchased ~3.0M PURR shares at avg cost $3.42; issued $38.4M in shares under equity facility at avg $6.31."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":3126000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112534,"accession_number":"0001193125-26-055449","cik":2078856,"company_name":"Hyperliquid Strategies Inc","ticker":"PURR","form_type":"8-K/A","filed_at":"2026-02-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Hyperliquid Strategies files audited Sonnet FY2025 financials after combo","event_type":"m_and_a","confidence":"medium","bullets":["Sonnet's audited financials for FY ended Sep 30, 2025 filed; pro forma data included.","Market value of Sonnet common equity held by non-affiliates: $4.15M as of Mar 31, 2025 ($1.34/share).","Sonnet is a clinical-stage oncology biotech with FHAB platform; lead SON-1010 in solid tumors.","Business combination closed Dec 2, 2025; Hyperliquid now wholly owns Sonnet.","Sonnet has history of operating losses and requires significant additional capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112535,"accession_number":"0001193125-26-045553","cik":2078856,"company_name":"Hyperliquid Strategies Inc","ticker":"PURR","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Hyperliquid Strategies reports $317.9M net loss for H1 FY2026; HYPE holdings 17.6M","event_type":"earnings","confidence":"high","bullets":["Six-month net loss of $317.9M, driven by $262.4M unrealized loss on HYPE tokens and $35.6M IPR&D write-off.","Revenue from interest ($0.9M) and staking ($0.5M); total assets $616.7M with no debt and stockholders' equity $589.8M.","Treasury deployed $129.5M to acquire 5M HYPE tokens, raising total holdings to 17.6M; $125M deployable capital remains.","Repurchased 3M PURR shares for $10.5M, reducing diluted share count to 150.6M.","Completed NASDAQ listing Dec 2, 2025 via business combination with Sonnet BioTherapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":-15.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":500000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129138,"accession_number":"0001193125-25-310714","cik":2078856,"company_name":"Hyperliquid Strategies Inc","ticker":"PURR","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Hyperliquid Strategies announces $30M share repurchase program","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $30M of common stock over 12 months.","Repurchases in open market or private transactions at management's discretion.","CEO says program aims to increase per-share exposure to HYPE token efficiently.","No guarantee of number of shares; program may be suspended at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129137,"accession_number":"0001493152-25-025886","cik":2078856,"company_name":"Hyperliquid Strategies Inc","ticker":"PURR","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["2.01","1.01","3.02","3.03","5.03","5.01","5.02","5.05","7.01","8.01","9.01"],"status":"ready","headline":"Hyperliquid Strategies completes business combination; trades as PURR on Nasdaq Dec 3","event_type":"m_and_a","confidence":"high","bullets":["Closed acquisition of Sonnet BioTherapeutics and Rorschach I LLC; combined entity has ~127M shares outstanding.","New board of eight directors including Bob Diamond, Eric Rosengren, Thomas King; David Schamis remains CEO.","Issued to advisor warrants for up to 27.4M shares at exercise prices $9.375, $12.50, and $18.75.","Stock begins trading on Nasdaq Capital Market under ticker PURR on December 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}